Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00662259 · ClinicalTrials.gov registry record · Phase 4
Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder
A Phase 4 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT00662259 is a Phase 4 study that has completed, run by University of California, San Diego. The registered enrollment target is 32 participants.
The verdict
NCT00662259, a Phase 4 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to find out how an anti-anxiety drug or placebo affects the activity of your brain when you are at rest and when you are viewing emotional material, such as, emotional faces and pictures.
Interventions
- DRUG Placebo
- DRUG Alprazolam (Xanax)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00662259
The ClinicalTrials.gov registry entry for NCT00662259 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00662259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00662259 about?
NCT00662259 is a clinical study titled "Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder". The purpose of this study is to find out how an anti-anxiety drug or placebo affects the activity of your brain when you are at rest and when you are viewing emotional material, such as, emotional faces and pictures.
What is the current status of trial NCT00662259?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2008-04. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00662259?
The interventions under investigation include: Placebo (DRUG), Alprazolam (Xanax) (DRUG).
Who is sponsoring clinical trial NCT00662259?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.